Last updated 30 days ago
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
1150 patients around the world
Available in Argentina, Mexico, United States, Brazil, Spain
Hoffmann-La Roche
46Research sites
1150Patients around the world
This study is for people with
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Hospital Provincial del Centenario - Rosario, Santa Fe
Recruiting
CEMIC - Hospital Universitario Sede Saavedra - CABA, Buenos Aires
Recruiting
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Recruiting
Instituto de Oncología Ángel H. Roffo - CABA, Buenos Aires
Recruiting
Centro Oncológico Korben
Recruiting
Hospital Alemán
Recruiting
Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária
Recruiting
Núcleo de Pesquisa Clinica São Camilo
Recruiting
Hospital Sao Rafael
Recruiting
Centro Regional Integrado de Oncologia - CRIO
Recruiting
StudyAstefania
SponsorHoffmann-La Roche
Study typeInterventional
Conditions
Breast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04873362
